Organization
Medical Faculty Mannheim
10 abstracts
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.Org: Royal Cancer Hospital, Heidelberg University, Department of Oncology, National Taiwan University Hospital, Asan Medical Center, Service de Oncología Médica,
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.Org: Danish Colorectal Cancer Center South, Vejle Hospital, Gastro Unit, Department of Oncology, National Taiwan University Hospital, Department of Oncology and Palliative Units,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
INTRAMET: Results of a prospective, single-arm, open-label phase II trial of intraoperative radiotherapy after resection of brain metastases.Org: University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Hospital, Heidelberg, Germany, University Hospital Bonn, University of Bonn,
Abstract
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.Org: Medical Oncology Group, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Efficacy and safety of induction chemotherapy with docetaxel + cisplatin in selected groups of patients with HNSCC.Org: Pavlov University, Saint-Petersburg, Russian Federation, Saint-Petersburg State University, Medical Faculty Mannheim, SPb SBIH City clinical oncology dispensary,
Abstract
ASSOCIATION BETWEEN HLA-DRB1*04 HISTOCOMPATIBILITY COMPLEX AND RHEUMATOID ARTHRITIS IN MACEDONIAN POPULATIONOrg: Clinic of Rheumatology, University of Lübeck, Lübeck, Clinical Center-Skopje, Institute of Immunobiology and Human Genetics, Medical Faculty Mannheim, Skopje,